Sign in
Taking people in United StatesPhase 1

Tests tagraxofusp, alone or with chemotherapy, in children with relapsed blood cancers

Tests tagraxofusp, alone or with chemotherapy, in children with returning blood cancers.

Key facts

Who runs it
Therapeutic Advances in Childhood Leukemia Consortium
Where
Ann Arbor, Atlanta, Baltimore, Bethesda, Boston, Charlotte, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Denver, Fort Worth, Houston, Indianapolis, Los Angeles, Memphis, Miami, Milwaukee, Minneapolis, New York, Orange, Philadelphia, Portland, Salt Lake City, San Francisco, Seattle, and Washington D.C., United StatesSee the 29 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
54 people, planned
Started
11 Nov 2022
Expected to end
11 Nov 2027
Type of study
Interventional, 4 groups
Treatments tested
  • Tagraxofusp
  • Fludarabine
  • Cytarabine
  • Dexamethasone
  • Vincristine
  • Azacitidine
  • Methotrexate
  • Cytarabine IT
  • Hydrocortisone
Record updated
6 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults whose blood cancer has come back or has not responded to treatment, and whose cancer cells carry CD123.

Age
From 1 to 21 years old.
Sex
All sexes can join.
Disease stage
Blood cancer (leukemia, lymphoma, myelodysplastic syndrome, or BPDCN) that came back or did not respond to treatment. Part 1 needs a second or later relapse, or no response after 2 or more chemotherapy cycles. Part 2 allows a first or later relapse.
Earlier treatment
Must have recovered from side effects of earlier treatment. At least 14 days must have passed since chemotherapy that lowers blood counts. Earlier tagraxofusp is not allowed. Other drugs aimed at CD123 are allowed.
Biomarker or test result
Tumor cells must show CD123 on their surface, tested at the local hospital.

Main reasons for not taking part

  • Cancer in the brain or spinal fluid (cannot join Part 1)
  • Cancer only in the brain or spinal fluid (cannot join either part)
  • Earlier treatment with tagraxofusp
  • Active infection that needs treatment through a vein
  • DNA fragility syndromes such as Fanconi anemia or Bloom syndrome

The registry criteria, word for word

Show all 62 criteriaShow less

Who can take part

  • Age
  • Patients must be ≥ 1 and ≤21 years of age at the time of study enrollment; Diagnosis
  • Relapsed and/or refractory hematologic malignancy (including, but not limited to, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, mixed phenotype acute leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, and non-Hodgkin lymphoma)
  • Tumor cells must demonstrate surface expression of CD123 at the time of enrollment by flow cytometry or immunohistochemistry, as defined by the local institution; Disease Status:; Monotherapy, Part 1
  • Second or greater relapse; or
  • Refractory after 2 or more chemotherapy cycles; or
  • First relapse after primary chemotherapy-refractory disease; or
  • BPDCN in first relapse or refractory after 1 or more chemotherapy cycles; Combination therapy, Part 2
  • First or greater relapse; or
  • Refractory after 2 or more chemotherapy cycles; or
  • BPDCN in first relapse or refractory after 1 or more chemotherapy cycles; For relapsed/refractory leukemia, patients must have:
  • >5% blasts in the bone marrow aspirate or biopsy by morphology or flow cytometry
  • Patients with 1% - 5% blasts are eligible for Part 2, Cohort C (only), if A single bone marrow sample with flow cytometry and at least one other test (e.g. karyotype, FISH, PCR, or NGS) shows ≥ 1% leukemic blasts and/or flow cytometry demonstrates a stable or rising level of disease on two serial bone marrows; For relapsed/refractory non-Hodgkin or Hodgkin lymphoma, patients must have:
  • Histologic verification of relapse
  • Measurable disease documented by radiographic criteria or bone marrow
  • Patients in Part 1 may have sites of non-CNS extramedullary disease, but no CNS disease. Patients in Part 2 may have CNS disease and/or other non-CNS extramedullary disease. No cranial irradiation is allowed during the protocol therapy
  • Patients with Down syndrome are eligible to participate in Part 1 only; Performance Level
  • Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ≤ 16 years of age (See Appendix I for Performance Scales). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score; Prior Therapy
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy, defined as resolution of all such toxicities to ≤ Grade 2 or lower per the inclusion/exclusion criteria; Myelosuppressive chemotherapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. At least 14 day must have elapsed since the completion of myelosuppressive therapy. However, individuals may receive any of the following medications within 14 days without a "wash-out period":
  • Hydroxyurea: Hydroxyurea can be initiated and/or continued for up to 24 hours prior to the start of protocol therapy
  • "Maintenance-style" therapy: therapy including vincristine (dosed a maximum of one-time weekly), oral 6-mercaptopurine, oral methotrexate (dosed a maximum of one-time weekly), intrathecal therapy (dosed a maximum of one-time weekly) and/or dexamethasone (dosed at ≤3 mg/m2/dose twice daily) or prednisone (dosed at ≤20 mg/m2/dose twice daily) can be continued for up to 24 hours prior to entering the study
  • Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD) and are at least 100 days post-transplant at the time of enrollment
  • Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with granulocyte colony stimulating factor (GCSF) or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®)
  • Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
  • Monoclonal antibodies: Maximum of 3 half-lives of the antibody or 21 days (whichever is shorter) must have elapsed after the last dose of monoclonal antibody
  • Immunotherapy: At least 30 days from last infusion of chimeric antigen receptor T cell (CART) therapy or tumor vaccine
  • Radiation Therapy (XRT):; ≥ 84 days must have passed, from the end of therapy, if patient received prior total body irradiation (TBI); ≥ 42 days must have passed, from the end of therapy, if patient received craniospinal irradiation (CSI); ≥ 14 days must have passed after whole brain radiotherapy or stereotactic radiation therapy; No washout period is required for:; Extramedullary site other than CNS that is a maximum 10 x 10 cm total radiation non-CNS field. If the field is > 10 x 10 cm, a 14-day washout period is required. ii. Local ocular radiotherapy as long as subject has measurable/evaluable disease outside the radiation port
  • Patients that have received other non-tagraxofusp CD123 targeting agents are eligible. Patients that have previously received tagraxofusp are not eligible; Organ Function Requirements; Adequate Bone Marrow Function Defined as:
  • Patients should not be known to be refractory to red blood cell or platelet transfusions
  • Blood counts are not required to be normal prior to enrollment on trial. However, platelet count must be ≥20,000/mm3 to initiate therapy (may receive platelet transfusions); Adequate Renal Function Defined as:
  • Patient must have a calculated creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender in the chart below:; Maximum Serum Creatinine (mg/dL):
  • 1 to < 2 years old - Male: 0.6, Female: 0.6
  • 2 to < 6 years old - Male:0.8, Female: 0.8
  • 6 to < 10 years old - Male: 1, Female: 1
  • 10 to < 13 years old - Male: 1.2, Female: 1.2
  • 13 to < 16 years old - Male: 1.5, Female: 1.4
  • ≥ 16 years old - Male: 1.7, Female: 1.4; The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC; Adequate Liver Function Defined as:
  • Total bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x institutional upper limit of normal for age
  • SGPT (ALT) and SGOT (AST) must be less than 3x institutional upper limit of normal
  • Serum albumin ≥3.2 g/dL (albumin infusion independent); Adequate Cardiac Function Defined as:
  • Shortening fraction of ≥27% by echocardiogram, or
  • Ejection fraction of ≥ 50% by gated radionuclide study/echocardiogram; Adequate Pulmonary Function Defined as:
  • Pulse oximetry > 94% on room air (> 90% if at high altitude)
  • No evidence of dyspnea at rest and no exercise intolerance; Reproductive Function
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment
  • Female patients with infants must agree not to breastfeed their infants while on this study
  • Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 12 weeks after the last dose of tagraxofusp

Who cannot take part

  • Patients with isolated non-CNS disease are eligible for Part 1 and Part 2; Concomitant Medications
  • Corticosteroids - Patients receiving corticosteroids for disease control who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible
  • Investigational Drugs - Patients who are currently receiving another investigational drug are not eligible. The definition of "investigational" for use in this protocol means any drug that is not licensed by the FDA, Health Canada or the Therapeutic Goods Administration to be sold in the countries they govern. (United States, Canada and Australia)
  • Anti-cancer Agents - Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible [with the exceptions being laid out in the inclusion criteria under 'Prior Therapy']. Intrathecal chemotherapy (at the discretion of the primary oncologist) may be given up to one week prior to the initiation of study treatment (day 1 therapy)
  • Anti-GVHD or agents to prevent organ rejection post-transplant - Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. At least 4 weeks must have elapsed after the last dose of GVHD meds; Infection Criteria - Patients are excluded if they have:
  • Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability
  • Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results
  • Disease Status:
  • Patients with CNS disease are not eligible for Part 1
  • Patients with isolated CNS disease are not eligible for Part 1 or Part 2
  • Active fungal, viral, bacterial, or protozoal infection requiring IV treatment. Chronic prophylaxis therapy to prevent infections is allowed
  • Patients will be excluded if they have a known allergy to any of the drugs used in the study
  • Patients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded
  • Positive blood culture within 48 hours of study enrollment
  • A positive fungal culture within 30 days of study enrollment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 21 years old?

Where in United States

Also in 1 other country, 2 sites

  • C S Mott Children's HospitalAnn Arbor, United StatesContact: Rajen Mody, MD (principal investigator)Taking people
  • Children's Healthcare of Atlanta, Emory UniversityAtlanta, United StatesContact: Melinda Pauly, MD (principal investigator)Not yet recruiting
  • Johns Hopkins UniversityBaltimore, United StatesContact: Pat Brown, MD (principal investigator)Not yet recruiting
  • National Cancer Institute Pediatric Oncology BranchBethesda, United StatesContact: Nirali Shah, MD (principal investigator)Not yet recruiting
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Andrew Place, MD (principal investigator)Not yet recruiting
  • Carolina-Levine Children's HospitalCharlotte, United StatesContact: Joel Kaplan, MD (principal investigator)Not yet recruiting
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Jenna Rossoff, MD (principal investigator)Taking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Robin Norris, MDTaking people
  • Rainbow BabiesCleveland, United StatesContact: Rachel Egler, MD (principal investigator)Not yet recruiting
  • Nationwide Children's HospitalColumbus, United StatesContact: Susan Vear-Colace, MD (principal investigator)Not yet recruiting
  • University of Texas, SouthwesternDallas, United StatesContact: Tamra Slone, MDTaking people
  • Children's Hospital ColoradoDenver, United StatesContact: Margaret Macy, MD (principal investigator)Taking people
  • Cook Children's HospitalFort Worth, United StatesContact: Kenneth Heym, MD (principal investigator)Taking people
  • Texas Children's Hospital/ Baylor College of MedicineHouston, United StatesContact: Eric Schafer, MDTaking people
  • Riley Hospital for ChildrenIndianapolis, United StatesContact: Sandeep Batra, MDTaking people
  • Children's Hospital Los AngelesLos Angeles, United StatesContact: Alan Wayne, MD (principal investigator)Taking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Jeffrey Rubnitz, MDNot yet recruiting
  • University of MiamiMiami, United StatesContact: Julio Barredo, MDNot yet recruiting
  • Children's Hospital of WisconsinMilwaukee, United StatesContact: Zachary Graff, MD (principal investigator)Taking people
  • Children's Hospital and Clinics of MinnesotaMinneapolis, United StatesContact: Nathan Gossai, MDNot yet recruiting
  • Children's Hospital New York-PresbyterianNew York, United StatesContact: Nobuko Hijiya, MD (principal investigator)Not yet recruiting
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Maria Sulis, MD, MSTaking people
  • Children's Hospital Orange CountyOrange, United StatesContact: Van Thu Huynh, MD (principal investigator)Not yet recruiting
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Sue Rheingold, MD (principal investigator)Not yet recruiting
  • Oregon Health Science UniversityPortland, United StatesContact: Bill Chang, MD (principal investigator)Not yet recruiting
  • Primary Children's HospitalSalt Lake City, United StatesContact: Anupam Verma, MD (principal investigator)Taking people
  • UCSF School of MedicineSan Francisco, United StatesContact: Michelle Hermiston, MD (principal investigator)Taking people
  • Seattle Children's HospitalSeattle, United StatesContact: Adam Lamble, MD (principal investigator)Not yet recruiting
  • Children's National Medical CenterWashington D.C., United StatesContact: Reuven Schore, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies.

Read full original descriptionShow less

The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells.

The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date.

This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy.

The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.

About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.

The 4 groups in the trial

  • Part 1Treatment being tested

    Tagraxofusp -Days 1-5 IT Therapy (may include methotrexate, cytarabine, or triple IT) * Day 1 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator

    Treatment: Tagraxofusp, Methotrexate, Cytarabine IT, and Hydrocortisone

  • Part 2 - Cohort ATreatment being tested

    Tagraxofsup -Days 4-8 Fludarabine -Days 1-5 Cytarabine -Days 1-5 IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy * Day 1 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator CNS2/3 IT Therapy * Days 1, 8, 15, and 22 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator

    Treatment: Tagraxofusp, Fludarabine, Cytarabine, Methotrexate, Cytarabine IT, and Hydrocortisone

  • Part 2 - Cohort BTreatment being tested

    Tagraxofsup -Days 8-12 Dexamethasone -Days 1-5 Vincristine -Days 1, 8, 15, and 22 IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy * Day 1 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator CNS2/3 IT Therapy * Days 1, 8, 15, and 22 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator

    Treatment: Tagraxofusp, Dexamethasone, Vincristine, Methotrexate, Cytarabine IT, and Hydrocortisone

  • Part 2 - Cohort CTreatment being tested

    Tagraxofsup -Days 1-5 Azacitidine -Days 1-5 IT Therapy (may include methotrexate, cytarabine, or triple IT) CNS1 IT Therapy * Day 1 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator CNS2/3 IT Therapy * Days 1, 8, 15, and 22 * Patients may receive additional IT therapy with their end-of-cycle disease re-evaluation at the discretion of the treating investigator

    Treatment: Tagraxofusp, Azacitidine, Methotrexate, Cytarabine IT, and Hydrocortisone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Plain-language title
Tests tagraxofusp, alone or with chemotherapy, in children with relapsed blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05476770, who can take part
Record updated
6 December 2024